BartÅ, omiej Pochwat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4208328/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Zinc Deficiency Blunts the Effectiveness of Antidepressants in the Olfactory Bulbectomy Model of Depression in Rats. Nutrients, 2022, 14, 2746.	4.1	2
2	Ketamine - a long way from anesthetic to a prototype antidepressant: Review of potential mechanisms of action. Psychiatria Polska, 2021, , 1-16.	0.5	2
3	Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction. International Journal of Molecular Sciences, 2020, 21, 4791.	4.1	5
4	An update on NMDA antagonists in depression. Expert Review of Neurotherapeutics, 2019, 19, 1055-1067.	2.8	39
5	Antidepressant-like activity of hyperforin and changes in BDNF and zinc levels in mice exposed to chronic unpredictable mild stress. Behavioural Brain Research, 2019, 372, 112045.	2.2	33
6	Characterization of the Brain Penetrant Neuropeptide Y Y2 Receptor Antagonist SF-11. ACS Chemical Neuroscience, 2019, 10, 3454-3463.	3.5	7
7	Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice. Frontiers in Molecular Neuroscience, 2018, 11, 456.	2.9	29
8	Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence. Psychopharmacology, 2017, 234, 631-645.	3.1	16
9	Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats. Neuropharmacology, 2017, 125, 333-342.	4.1	32
10	The level of the zinc homeostasis regulating proteins in the brain of rats subjected to olfactory bulbectomy model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 36-48.	4.8	14
11	Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology, 2016, 233, 2901-2914.	3.1	37
12	Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats. Pharmacological Reports, 2016, 68, 881-885.	3.3	7
13	Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies. Molecular Neurobiology, 2016, 53, 6869-6881.	4.0	30
14	Relationship between Zinc (Zn2+) and Glutamate Receptors in the Processes Underlying Neurodegeneration. Neural Plasticity, 2015, 2015, 1-9.	2.2	39
15	Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. Psychopharmacology, 2015, 232, 355-367.	3.1	44
16	Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. Neuropharmacology, 2015, 99, 517-526.	4.1	40
17	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 254-263.	4.8	43
18	Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. International Journal of Neuropsychopharmacology, 2014, 17, 393-405.	2.1	54

#	Article	IF	CITATIONS
19	NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs, 2014, 23, 1181-1192.	4.1	40
20	Zinc as a marker of affective disorders. Pharmacological Reports, 2013, 65, 1512-1518.	3.3	66
21	Synthesis and biological evaluation of new derivatives of 2-substituted 4-hydroxybutanamides as GABA uptake inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 183-190.	5.5	18